### Gastroesophageal Reflux Disease

Neil Crittenden

April 24, 2014

### Outline

- Pathology:
  - Mechanics
  - Chemistry
- Clinical:
  - GERD Basics
  - Refractory GERD Management
  - Future techniques in testing

### Introduction

- In western countries 10-30% of individuals affected every week
- Gastroesophageal reflux disease (GERD):
- Non-Erosive Reflux Disease (NERD): 70%
  - Those that do not develop esophageal erosions
  - Usually normal LES resting pressure, minimal motility abnormalities, low acid exposure, minimal night-time acid exposure, lower response to PPI
- Erosive Reflux Disease (ERD)
  - erosive esophagitis

Altomare A, Guarino MP, Cocca S, Emerenziani S, Cicala M. Gastroesophageal reflux disease: Update on inflammation and symptom perception. World J Gastroenterol2013 Oct 21;19(39):6523-8.


### **Pathology Outline**

- Mechanics
- Chemical Hypothesis

- LES has 2 components:
  - Internal Sphincter
  - Diaphragmatic Crura
- Flat valve of the proximal stomach

- LES has 2 components:
  - Internal Sphincter
    - Circular Smooth Muscle 3-4 cm across the squamocolumnaar junction
    - Tonically Contracted
    - Relaxes only during swallowing, secondary peristalsis and during TLERs
  - Diaphragmatic Crura
- Flat valve of the proximal stomach


- LES has 2 components:
  - Internal Sphincter
  - Diaphragmatic Crura
    - Exerts pressure on the LES
    - Maintained by phrenoesophageal ligaments
- Flat valve of the proximal stomach



**Fig. 2.** Anatomy of the gastroesophageal junction.

Lee YY, McColl KE. Pathophysiology of gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol2013 Jun;27(3):339-51

- LES has 2 components:
  - Internal Sphincter
  - Diaphragmatic Crura
- Flat valve of the proximal stomach
  - formed by the gastric sling fibers also helps prevent reflux



**Fig. 2.** Anatomy of the gastroesophageal junction.

Lee YY, McColl KE. Pathophysiology of gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol2013 Jun;27(3):339-51

#### **Acid Pocket**


- An area of post-prandial unbuffered gastric acidity immediately distal to the gastroesophageal junction
- Enlarged in patients with hiatus hernia
- Provides a reservoir of acid available to reflux when the intrinsic sphincter fails

### Acid Pocket: Paradox

- Most reflux symptoms are post-prandial
- Intragastric juices are LEAST acidic (pH 3-5) during the post-prandial period because of buffering with food
- During fasting, gastric juice is highly acidic
   with a pH ~ 1


### Acid Pocket: Paradox

- pH just distal to the GEJ remains highly acidic after meals and seems to escape the buffering effect of the meal
- Gastric cardia region becomes more acidic after a meal in contrast to the rest of the stomach which becomes less acidic



### Acid pocket may be acid coating

- Linear sensors oversimplify the model
- The ones in the middle are near food bolus in the lumen and the acidic sensors are in contact with the walls/sphincter
- "Acid Coat" more likely



### **GERD Aggravating Factors**

- Central Obesity
- Gastric Acidity
- Congenital
- Gastric Emptying

## **Central Obesity**




### **Central Obesity**

- Increases intra-abdominal pressure
- Increases the GE pressure gradient
- Increased pressure pushes EGJ into the chest predisposing to hiatus hernia


- Standard pH measurement is at 5 cm proximal to the upper boarder of the LES to prevent artificial detection during TLESRs, but it will only detect reflux completely across the LES
- Measuring Intrasphincteric reflux (reflux <5 cm above GEJ) the following observations were made:

 With larger waist circumference the squamocolumnar junction was positioned closer to the upper boarder of the LES




Robertson EV, Derakhshan MH, Wirz AA, Lee YY, Seenan JP, Ballantyne SA, Hanvey SL, Kelman AW, Going JJ, McColl KE. Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology2013 Oct:145(4):730-9

 With larger waist circumference the Esophageal/Gastric acid transition was positioned closer to the upper boarder of the LES




Robertson EV, Derakhshan MH, Wirz AA, Lee YY, Seenan JP, Ballantyne SA, Hanvey SL, Kelman AW, Going JJ, McColl KE. Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology2013 Oct:145(4):730-9


 With larger waist circumference the length of nonacid secreting cardia mucosa was shorter



Robertson EV, Derakhshan MH, Wirz AA, Lee YY, Seenan JP, Ballantyne SA, Hanvey SL, Kelman AW, Going JJ, McColl KE. Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology2013 Oct:145(4):730-9



Lee YY, McColl KE. Pathophysiology of gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol2013 Jun;27(3):339-51



Color= Mean % time pH<4 within GEJ and stomach (dark red >30% and light red 4-30%).

PIP=Pressure Inversion Point

pLOS= Peak LOS pressure

Grey Box is High Pressure Zone

Lee YY, McColl KE. Pathophysiology of gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol2013 Jun;27(3):339-51

### Pathogenesis: Hypothesis

- Damage by Refluxate:
  - Gastric juice stimulates esophageal epithelial cells to secrete chemokines

Chemokines attract and activate immune cells

Immune cells damage esophageal squamous epithelial cells

### Pathogenesis: Hypothesis

- Both ERD and NERD patients have cytokines, but different ones
- ERD have higher cytokine interleukin-8 (IL-8)
   and chemokine platelet activating factor (PAF).

### Pathogenesis: Hypothesis

- Both ERD and NERD patients have over expression of TRPV1
- Acid activates TRPV1 and the PAF is synthesized, leading to the cytokine cascade

Patients	Chemokines
GEKD ERD	PAF <sup>[11,36,37]</sup> , MCP-1 <sup>[9-11,36,38]</sup> , RANTES <sup>[9,36]</sup> , MIP1- $\alpha$ <sup>[11,36,38]</sup> , Eotaxin-1, Eotaxin-2 and Eotaxin-3 <sup>[11,36]</sup> , CINC-2 $\alpha$ <sup>[38]</sup> , and ICAM-1 <sup>[38]</sup>
NEND	

Barrett's esoph

### Why the pain?

 90% of ERD and 2/3 of NERD patients have dilation of intercellular spaces, papillary elongation and basal cell hyperplasia, so there may be a barrier problem as well

### Why the pain?

- Calcitonin-gene related peptide (CGRP)
- Substance P
  - Both are produced by sensory neurons located in the esophageal mucosal layer
  - Both can be activated by a different mechanism in:
    - ERD (inflammatory cascade + barrier problem)
    - NERD (increased sensitivity + barrier problem)

### NERD Pain... a few ideas...??

- Impaired mucosal barrier function may allow non-acid reflux to directly activation of pain receptors??
- Pain receptors may be activated by non-acid reflux induced distension of the esophagus??
- Increased sensitivity may be from up regulation of peripheral pain receptors and central sensitization of spinal neurons???

#### **Acid Pain**

- Acid-sensitive TRPV1 receptors in epithelial cells of mucosa produce:
  - CGRP
  - Substance P

#### **Acid Pain**

- Ionotrophic purinergic (P2X and P2Y)
   receptors, located on acid-sensitive nerves:
  - ATP from epithelial cell lining of GI, bladder and ureter may activate P2X in the sub-epithelial nerve plexus and the signal then goes via the spinal cord to the brain
- Acid-> activate TRPV1 (Sub P/CGRP & ATP) -> activates P2X in an autocrine fashion worsening the pain

Altomare A, Guarino MP, Cocca S, Emerenziani S, Cicala M. Gastroesophageal reflux disease: Update on inflammation and symptom perception. World J Gastroenterol2013 Oct 21;19(39):6523-8.

### Clinical

- GERD Basics
- Refractory GERD
- Future techniques in testing

- Montreal censenus defined GERD as:
  - "A condition which develops when the reflux of stomach contents causes <u>troublesome symptoms</u> and/or complications."
- Lifestyle Recommendations (Grade B)
  - Weight loss for overweight or obese patients
  - Elevation of the head of the bed in patients who are symptomatic when recumbent

#### • Treatment:

- If symptoms not controlled with once daily, try twice daily (Grade B)
- May use PPI as-needed
- Endoscopy (Grade B):
  - GERD with dysphagia, Bx any visual abnormalities
  - If no response to BID PPI

- Chronic Management:
  - Recommend AGAINST routine endoscopy in subjects with erosive or NERD to assess for disease progression
  - Long-term PPI should be titrated down to the lowest effective dose based on Symptom control (Grade A)
    - "The liklyhood of long-term spontaneous remission of disease is low"
    - Insufficient evidence to advise bone density studies, Ca supplements, H. pyplori screening or any other routine precaution because of PPI use.

#### Antireflux Surgery

- When surgery and PPI are judged to offer similar efficacy, use PPI's because of safety (Grade A)
- Patients responsive to, but intolerant of PPI's, consider surgery as an alternative (Grade A)
- Uncontrolled troublesome symptoms, especially regurgitation despite PPIs, the benefits of surgery should be weighed against the risks (dysphasia, flatulence, inability to belch) (Grade B)



Contents lists available at SciVerse ScienceDirect

#### Best Practice & Research Clinical Gastroenterology



7

## Management of the patient with incomplete response to PPI therapy



Peter J. Kahrilas, M.D., Professor a,\*, Guy Boeckxstaens, M.D., Professor b, Andre J.P.M. Smout, M.D., Professor c


<sup>&</sup>lt;sup>a</sup> Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

b Department of Gastroenterology, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospital Leuven, Catholic University Leuven, Leuven, Belgium

<sup>&</sup>lt;sup>c</sup> Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands


PPI efficacy for potential manifestations of GERD

Estimates based on available RCT data




### PPI efficacy for potential manifestations of GERD

Estimates based on available RCT data




PPI efficacy for potential manifestations of GERD

Estimates based on available RCT data





PPI efficacy for potential manifestations of GERD


Estimates based on available RCT data




- Estimated 10-40% of patients with 'GERD' have either an incomplete or no response to standard dose of PPI.
- PPI's can only reduce acid secretion











- Manometry is useful to determine correct positioning for pH electrode placement
- Detect the rare case in which achalasia was misdiagnosed as GERD
- May be helpful in diagnosing the rumination syndrome (effortless regurgitation of most meals following consumption without retching, nausea, heartburn or abdominal pain).



## To be on PPI or not to be...




### Argument to be OFF PPI


- The chance of <u>finding a positive</u>
   <u>correlation between the reflux</u>
   <u>symptoms and reflux events</u> in a
   pH-impedance study is greatest
   when the patient is studied OFF
   acid inhibitors
- Best when the Dx of GERD has not been established beyond a doubt


### Argument to be ON PPI


To establish whether the
 <u>remaining symptoms</u> ON PPI are
 reflux- related and thus that the
 measurement should be done
 while the PPI is continued



- Acid reflux events with pH </= 4</li>
- Nonacid or weakly acid are pH >4
- 48 or more reflux events in 24 h is abnormal







G, Smout AJ. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol2013

Kahrilas PJ, Boeckxstaens

Tricyclic antidepressants, Trazodone SSRI's Venlafaxine

positive symptom association pathological reflux

Alginate: Gaviscon in a variety of OTC Formulations in the US, Take PRN after meals


Baclofen may cause too high of sedation at therapeutic dosages

double-dose PPI alginate, baclofen?

**GERD** 

symptoms reflux-related

insufficient response?





#### **Gaviscon® Extra Strength Tablets**

Active ingredients include 160 mg of Aluminum Hydroxide and 105 mg of Magnesium Carbonate.



#### Gaviscon® Extra Strength Tablets (Cherry)

Active ingredients include 160 mg of Aluminum Hydroxide and 105 mg of Magnesium Carbonate.



### Gaviscon® Regular Strength Tablets

Active ingredients include 80 mg of Aluminum Hydroxide and 14.2 mg of Magnesium Trisilicate.

Gaviscon® Regular Strength Tablets are available at select retailers and at drugstore.com.



### Gaviscon® Regular Strength Liquid

Available in 12 fl. oz. bottles. Active ingredients include 95 mg of Aluminum Hydroxide and 358 mg of Magnesium Carbonate per tablespoon.



Gaviscon® Regular Strength Liquid is available at select retailers and at drugstore.com.




### Gaviscon® Extra Strength Liquid

Available in 12 fl. oz. bottles.



Active ingredients include 254 mg of Aluminum Hydroxide and 237.5 mg of Magnesium Carbonate per teaspoon.



## Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial

L Lundell, <sup>1</sup> S Attwood, <sup>2</sup> C Ell, <sup>3</sup> R Fiocca, <sup>4</sup> J-P Galmiche, <sup>5</sup> J Hatlebakk, <sup>6</sup> T Lind, <sup>7</sup> O Junghard, on behalf of the LOTUS trial collaborators

# <sup>1</sup> Department of Surgery, Karolinska University Hospital, Huddinge, Sweden; <sup>2</sup> Department of Surgery, North Tyneside General Hospital, North Shields, Tyne and Wear, UK; <sup>3</sup> Department of Gastroenterology, Dr Horst Schmidt-Hospital, Wiesbaden, Germany; <sup>4</sup> Department of Surgical and Morphological Sciences, Anatomic Pathology

### ABSTRACT


**Background:** With the introduction of laparoscopic antireflux surgery (LARS) for gastro-oesophageal reflux disease (GORD) along with the increasing efficacy of modern medical treatment, a direct comparison is warranted. The 3-year interim results of a randomised study comparing both the efficacy and safety of LARS and esomeprazole (ESO) are reported.

Methods: LOTUS is an open, parallel-group multicentre,

se, and the mechanical side effects and durability of the antireflux repair in particular.<sup>5-8</sup> Although the perioperative and postoperative courses have been facilitated by the introduction of the laparoscopic technology,<sup>9</sup> the results in community practice remain far from optimal, and data on the long-term efficacy of standardised laparoscopic antireflux surgery (LARS) are lacking.<sup>6-7</sup> The poor therapeutic results in community practice may be due to variability in procedures or lack of experi-

 Bottom Line: PPI = Surgery Effectiveness, but Surgery's risk > PPI's risk

## **Endoscopic Procedures for GERD**



A: Stretta Effect

B: Endocinch Device

C: NDP Plicator

• D: Results of the Esophyx

Device

Pandolfino JE, Krishnan K. Do endoscopic antireflux procedures fit in the current treatment paradigm of gastroesophageal reflux disease? Clin Gastroenterol Hepatol2014 Apr;12(4):544-54.


## **Endoscopic Trials**

- All the endoscopic systems for GERD have not proven benefit in sham-controlled trials
- Esophyx is the only one not disproven, in trials now
  - Creates a serosal-to-serosal plications
  - It is a flexiable catheter that contains a tissue retractor and fasteners.
  - The endoscope fits within the catheter
  - <a href="http://www.youtube.com/watch?v=qXS4jHCWNvo">http://www.youtube.com/watch?v=qXS4jHCWNvo</a>

### EsophyX for Transoral Incisionless Fundoplication (TIF): Innovative technology that enables transoral reconstructive surgery



EsophyX enables the creation of a 270°, 2-3cm esophagogastric fundoplication by using proprietary tissue manipulating elements and 12 or more full-thickness polypropylene fasteners. The device is used in conjunction with a flexible video endoscope, which provides visualization throughout the TIF procedure.



### **Future**

 LINX device: a ring of magnetic beads placed around the esophagus to bolster the EGJ during labaroscopic surgery

### How Does the LINX System Work?

The LINX System is a small flexible band of interlinked titanium beads with magnetic cores. The magnetic attraction between the beads is intended to help the LES resist opening to gastric pressures, preventing reflux from the stomach into the esophagus. (See Fig. 1) LINX is designed so that swallowing forces temporarily break the magnetic bond, allowing food and liquid to pass normally into the stomach. (See Fig. 2) Magnetic attraction of the device is designed to close the LES immediately after swallowing, restoring the body's natural barrier to reflux. (See Fig. 3).




Figure 1: The LINX System is designed to help the LES resist opening to gastric pressures.




Figure 2: The LINX System is designed to expand to allow for normal swallowing.




Figure 3: Magnetic attraction of the device is designed to close the LES immediately after swallowing.

### How is the LINX System Implanted?

The LINX System is placed around the esophagus just above the stomach using a common, minimally invasive surgical technique called laparoscopy. (See Fig. 1-3).




Figure 1: A precision sizing tool is used to determine the appropriate size LINX System.




Figure 2: The LINX System is positioned around the LES using suture tails.




Figure 3: The ends of the LINX System are aligned and joined for secure closure.

### **Future**

 EndoStim: Improves LES pressure without altering deglutitive relaxation

## **GERD**

- Questions?
- Comments?